HHS Secretary says 14 of 19 FDA-restricted peptides will return to compounding

On February 27, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. said on a podcast that about 14 of the 19 peptides on the FDA's Category 2 restricted compounding list would return to Category 1, the category that lets licensed compounding pharmacies prepare a substance under interim policy ^[1][2]. Category 2 lists bulk drug substances the FDA says may present significant safety risks ^[1].

The peptides expected to move back include BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, AOD-9604, GHK-Cu, selank, semax, KPV and MOTS-C, according to a pharmacist's account of the announcement ^[1]. About five others — melanotan II, GHRP-2, GHRP-6, LL-37 and PEG-MGF — are expected to stay restricted because of continuing safety concerns ^[1]. The formal FDA list had not been updated in the weeks after the announcement, so the substances were not yet officially reclassified ^[1].

Reports indicated the substances would come off Category 2 effective April 23, 2026, with the FDA's Pharmacy Compounding Advisory Committee scheduled to review them at its July 23 and 24, 2026 meeting ^[1][2].

What reclassification does and does not mean

A move from Category 2 to Category 1 governs only whether a licensed compounding pharmacy operating under Section 503A or 503B may legally prepare the substance ^[1]. It is not FDA approval. Approval requires phase 1 through phase 3 clinical trials, labeling review and manufacturing validation under a New Drug Application or Biologics License Application ^[1]. None of the peptides under discussion has gone through that process for the uses patients typically seek, and Category 1 status does not establish proven safety, proven efficacy or standardized dosing ^[1].

Why the restrictions were imposed

In late 2023, the FDA moved 19 widely used peptides to Category 2, citing concerns about immunogenicity, manufacturing impurities and a lack of robust human clinical trial data ^[1]. BPC-157 has well over 100 preclinical studies but only a handful of small human trials, none of which would meet the standard for drug approval ^[1]. TB-500 has no completed human randomized controlled trials ^[1].

On June 30, 2026, the FDA posted documents in which its scientists said there is insufficient evidence to support changing the designation for any of the seven peptides the panel will consider ^[2]. The review cites potential safety concerns and a lack of consistent data ^[2]. The panel is set to weigh evidence for specific uses including ulcerative colitis, wound healing, obesity and migraines ^[2]. It includes members with ties to the peptide industry, among them people who work for companies that offer injectable peptides ^[2].

"Not a day goes by where I don't have a number of patients asking me about peptides," said Dr. Alexander Weber, an orthopedic surgeon and chief of sports medicine at the University of Southern California who has published a review of the evidence. "My stock answer is that we just don't have enough data to support their use" ^[2].

Why it matters for patients

This does not cover FDA-approved GLP-1 medicines. Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo) are approved drugs and are not on the restricted list. The peptides under discussion are separate compounds marketed mainly for injuries, muscle recovery, metabolism and related wellness claims ^[1][2]. GLP-1 drugs are themselves synthetic peptides, so the two categories are easy to confuse ^[2].

Being legally compoundable is not the same as being proven. Even after a move to Category 1, there is no FDA finding that a peptide works for what it is prescribed for ^[1].

The 2023 restrictions pulled the peptides out of licensed pharmacy supply chains, but patient demand continued and much of it shifted to online sellers marketing "research use only" products with no sterility validation, standardized dosing or medical supervision ^[1][2]. Compounding pharmacies are unlikely to resume production at scale until the FDA formally updates its list and pharmacies source raw materials and complete batch and sterility validation ^[1][2].

What happens next

The Pharmacy Compounding Advisory Committee meets July 23 and 24, 2026, and is expected to make recommendations on seven peptides. It is then scheduled to reconvene in February to consider others ^[2]. Until the FDA formally updates its list, the legal status of the remaining peptides for compounding has not changed ^[1].